Second Genome and Evotec to Collaborate in Microbiome Discovery and Development
13 March 2015 - 5:46PM
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) and Second
Genome, Inc. today announced a collaboration in small
molecule-based discovery and development activities for the
treatment of microbiome-mediated diseases. The collaboration
comprises the identification and optimisation of novel compounds as
well as licence agreements for already existing assets developed by
Evotec. Second Genome's unique approach to identify and modulate
microbiome-mediated pathways will be further enhanced by the use
and the results of Evotec's integrated drug discovery platform.
As part of the collaboration, Second Genome and Evotec will work
together to screen microbiome-mediated targets of interest
identified by the Second Genome microbiome discovery platform with
Evotec's technology platform, chemical libraries and other
pre-clinical capabilities. The agreement between Evotec and Second
Genome triggers an undisclosed upfront payment. Evotec is also
eligible for pre-clinical, clinical and regulatory milestones as
well as royalty payments related to commercialisation.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec,
commented: "We are pleased to contribute to Second
Genome's unique approach to treat microbiome-mediated diseases in
the body with a particular emphasis on the gut. The enrichment and
maturation of Second Genome's project portfolio through our
contributions will enhance the Company's clinical pipeline in the
near future."
Mohan Iyer, Chief Business Officer of Second Genome,
added: "The partnership with Evotec allows us efficiently
to translate our unique microbiome discovery platform efficiently
into tangible drug molecules for clinical development. Our enriched
pipeline offers new treatment approaches for patients across a wide
range of diseases with an initial focus on inflammatory conditions.
We look forward to a sustained partnership with Evotec."
Further financial terms were not disclosed.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies,
academics, patient advocacy groups and venture capitalists. We
operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology, inflammation and infectious
diseases. Evotec has long-term discovery alliances with partners
including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen
Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition,
the Company has existing development partnerships and product
candidates both in clinical and pre-clinical development. These
include partnerships with Boehringer Ingelheim and MedImmune in the
field of diabetes, with Janssen Pharmaceuticals in the field of
depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
ABOUT SECOND GENOME
Second Genome's mission is to transform lives with medicines
developed through innovative microbiome science. Second Genome has
built a novel platform for microbiome drug discovery and is engaged
in active programmes in multiple areas of significant unmet medical
need. Please visit www.secondgenome.com for more information.
FORWARD LOOKING STATEMENTS — Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to
a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.
CONTACT: For further information, please contact
Gabriele Hansen
VP, Corporate Communications & Investor Relations
+49.(0)40.560 81-255
+49.(0)40.560 81-333 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jul 2023 to Jul 2024